KW—Iranian drones cost less than $50,000 to build and launch. Yet they are taking down multi-billion-dollar fixed assets all across the Persian Gulf. Just a few examples: Bahrain’s sole oil refinery, previously running over 400,000 bpd; the largest Mideast refinery, in the UAE, with capacity of over 900,000 bpd; the world’s busiest international airport; the American embassy and consulate in Iraq. Warfighters in Washington and Tel Aviv insist that the war against Iran, measured conventionally, is already over.
Kevin Walmsley
Kevin Walmsley
Kevin Walmsley grew up in Venice, Florida, which he still considers his hometown, no matter where he is this week. He has four grown children, Christopher, Briton, Lauren, and Megan. Kevin has lived in China since 2012, and works for Direct Equipment from Kunming. His team is a dedicated group of English-fluent Chinese engineers and logistics pros, who coordinate factory visits and inspections, perform quality control, ensure accurate order placement and fulfillment, and oversees DEC's freight forwarding relationships. Kevin is a nine-year veteran of the US Army, and is active in underground churches and missions in Southeast Asia.
-
-
China’s newest air force jets have next-generation radars. New USAF F-35’s have no radars at all.
Gallium Nitride semiconductors are crucial for advanced radar and missile guidance applications.Approx 6 Mins • Watch / readKEVIN WALMSLEY—Gallium Nitride semiconductors are crucial for advanced radar and missile guidance applications. China has a monopoly on gallium processing, and export bans on gallium for military use. Pentagon contractors cannot build radars for the F-35, among other platforms, because of supply chain issues related to gallium supplies. So they are delivering these aircraft with “ballast” in place of radar systems.
-
China is solving cancer and building miracle drugs. Wall Street buys them and charges 100x.
Approx 14 Mins • Watch / readKEVIN WALMSLEY—China’s biotech clusters are much larger, move much faster, and are much more innovative than in North America or Europe. Western pharmaceutical companies and Wall Street venture capital are very active in China’s biotech scene, investing billions for licensing rights to the most revolutionary drugs, to enjoy monopolistic profits outside China. This business model is worth hundreds of billions of dollars a year, while even single drugs made in China are worth tens of billions annually after approved for the US market.

